CytoDyn (CYDY) EBT Margin (2018 - 2022)
CytoDyn's EBT Margin was -247414.71% in fiscal Q4 2022 (quarter ended May 31, 2022).
Powered by 
Analysis
CytoDyn (CYDY) EBT Margin (2018 - 2022) Analysis & Trends
For FY2022 (ended May 31, 2022), EBT Margin at CytoDyn came in at -70273.33%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 0.13% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 27.75% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 26.27% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 45.21% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 36.90% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 20.41% |
| 10 | CytoDyn | 334.50 Mn | 285.65 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2022 | -247,414.71% |
| Nov 30, 2021 | -17,812.00% |
| Aug 31, 2021 | -110,578.05% |
| Nov 30, 2019 | -2,688.18% |
| Aug 31, 2019 | -2,626.26% |
| Nov 30, 2018 | -11,929.16% |
| Aug 31, 2018 | -13,775.75% |
API Access
CytoDyn EBT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebt-margin&ticker=CYDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebt-margin", "ticker": "CYDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebt-margin&ticker=CYDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();